Distribution · Southeast Asia · Announced 23 Oct 2026
Korea United Pharm → Dai Nam Ha Noi
Korea United Pharm signed a US$0.77 million export contract with Vietnam's Dai Nam Ha Noi JSC for its anticancer drug Hydrin (hydroxyurea) capsules, alongside a US$2.5 million Philippine oncology deal.
Parties: Korea United Pharm (South Korea) → Dai Nam Ha Noi JSC (Vietnam)
- Deal type
- Distribution
- Value
- $0.8m
- Territory
- Vietnam
- Therapeutic area
- Oncology
- Assets
- Hydrin; hydroxyurea
- Announced
- 23 Oct 2026
Our analysis
Why this matters
Korea United Pharm has signed a US$0.77 million export contract with Dai Nam Ha Noi JSC of Vietnam for Hydrin capsules (hydroxyurea 500 mg), its flagship anticancer product. The contract was signed on 21 October 2026 at the Global Bio & Pharma Plaza (GBPP) 2026 export fair at KINTEX and announced on 23 October, alongside a US$2.5 million Philippine oncology contract with Qualimed Pharma. The contract term was not disclosed.
The company frames the deals as evidence of its anticancer products' competitiveness in a growing Southeast Asian market and plans to add further export lines in Vietnam.
The full analysis is free to read with a work email on this page.
Source: Medicopharma